{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:39:58Z","timestamp":1789853998068,"version":"4.0.1"},"reference-count":8,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,12,27]],"date-time":"2014-12-27T00:00:00Z","timestamp":1419638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2014,12,27]],"date-time":"2014-12-27T00:00:00Z","timestamp":1419638400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2015,4]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n A draft version of part 1 (Non\u2010Motor Aspects of Experiences of Daily Living; nM\u2010EDL) of the MDS\u2010UPDRS scale was employed as a secondary outcome in the ADAGIO study, which assessed the effect of rasagiline in early Parkinson's disease (PD) patients.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This analysis includes 1,150 untreated PD patients randomized to placebo or rasagiline 1 or 2 mg\/day for 36 weeks in the placebo\u2010controlled phase of ADAGIO who had draft\u2010nM\u2010EDL assessments at baseline and week 36.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Over the 9\u2010month placebo\u2010controlled phase of the study, nM\u2010EDL scores significantly deteriorated from baseline in the placebo group only (0.34\u2009\u00b1\u20090.10 units;\n P<\/jats:italic>\n \u2009<\u20090.001). Compared to the placebo group (n\u2009=\u2009583), there was significantly less deterioration in the 1\u2010mg\/day rasagiline group (n\u2009=\u2009280; treatment effect: \u22120.33 units;\n P<\/jats:italic>\n \u2009<\u20090.05), whereas the treatment effect in the 2\u2010mg\/day rasagiline group (n\u2009=\u2009287) was not statistically significant (\u22120.25\u2009\u00b1\u20090.17 units;\n P<\/jats:italic>\n \u2009=\u20090.131).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The nM\u2010EDL subscale appears sensitive to change in very early PD, and treatment with rasagiline 1 mg\/day was associated with significantly less decline in nonmotor experiences of daily living versus placebo. Given that score changes were numerically small, the clinical implications of this effect remain unclear. \u00a9 2014 International Parkinson and Movement Disorder Society<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/mds.26124","type":"journal-article","created":{"date-parts":[[2014,12,27]],"date-time":"2014-12-27T11:38:44Z","timestamp":1419680324000},"page":"589-592","source":"Crossref","is-referenced-by-count":23,"title":["Effects of rasagiline on the progression of nonmotor scores of the MDS\u2010UPDRS"],"prefix":"10.1002","volume":"30","author":[{"given":"Werner","family":"Poewe","sequence":"first","affiliation":[{"name":"Department of Neurology Innsbruck Medical University Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[{"name":"Parkinson's Disease and Movement Disorders Center NPF Center of Excellence, University of South Florida Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Neurology Toronto Western Hospital Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70373-8"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-005-0072-6"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20105"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23939"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25671"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809335"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70073-4"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.26124","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.26124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.26124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mds.26124","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.26124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:57:19Z","timestamp":1786629439000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.26124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,27]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1002\/mds.26124"],"URL":"https:\/\/doi.org\/10.1002\/mds.26124","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,27]]}}}